Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (13379)	4/1/2004 12:11:21 PM
From: Ron Nairn	Read Replies (1) \| Respond to of 14101

Well summarized Jim. At this juncture and forward, sales, funding sources and approvals are the whole story. Rondo

To: axial who wrote (13379)	4/5/2004 6:33:03 AM
From: twentyfirstcenturyfox	Read Replies (1) \| Respond to of 14101

Jim, Good summary of the past 3 years. Cal, I don't think these new rules would have helped us, during that time. What do you think? Cal posted short time ago ('cuse the lack of a post ref.) in greater depth on what follows. My take is, that the critical issue, alongside cash flow, is that time IS being allowed to pass by and no new drugs move in the pipeline. We have drug pipeline constipation. The opportunity cost of making management decisions which have a consequence of, say, Fungoff being delayed from coming to market one year sooner is NOT the first years profits (which may be minimal). Rather, it is the FINAL year's profits, viz., the year just before the drug loses it patent protection to generic competition. It is a bewildering state of afffairs. To paraphrase you, Jim, let's call it Onetrickpony Sales Corp. Fox.